Cargando…

KLRF1, a novel marker of CD56(bright) NK cells, predicts improved survival for patients with locally advanced bladder cancer

BACKGROUND: Bladder tumor‐infiltrating CD56(bright) NK cells are more tumor cytotoxic than their CD56(dim) counterparts. Identification of NK cell subsets is labor‐intensive and has limited utility in the clinical setting. Here, we sought to identify a surrogate marker of bladder CD56(bright) NK cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukherjee, Neelam, Ji, Niannian, Tan, Xi, Chen, Chun‐Liang, Noel, Onika D. V., Rodriguez‐Padron, Maria, Lin, Chun‐Lin, Alonzo, David G., Huang, Tim H., Svatek, Robert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134305/ https://www.ncbi.nlm.nih.gov/pubmed/36583228 http://dx.doi.org/10.1002/cam4.5579

Ejemplares similares

Intratumoral CD56(bright) natural killer cells are associated with improved survival in bladder cancer
por: Mukherjee, Neelam, et al.
Publicado: (2018)

Bladder tumor ILC1s undergo Th17‐like differentiation in human bladder cancer
por: Mukherjee, Neelam, et al.
Publicado: (2021)

The Increased Ratio of Blood CD56(bright) NK to CD56(dim) NK Is a Distinguishing Feature of Primary Sjögren's Syndrome
por: Ming, Bingxia, et al.
Publicado: (2020)

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation
por: Reyes, Ryan M, et al.
Publicado: (2021)

Reduction of the CD16(−)CD56(bright) NK Cell Subset Precedes NK Cell Dysfunction in Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Oncolytic virus treatment differentially affects the CD56(dim) and CD56(bright) NK cell subsets in vivo and regulates a spectrum of human NK cell activity
por: Wantoch, Michelle, et al.
Publicado: (2022)

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma
por: Seymour, Frances, et al.
Publicado: (2022)

Ageing is associated with a decline in peripheral blood CD56(bright )NK cells
por: Chidrawar, Shivani M, et al.
Publicado: (2006)

Circulating CD56(bright) NK cells inversely correlate with survival of melanoma patients
por: de Jonge, Kaat, et al.
Publicado: (2019)

Loss of CCR7 Expression on CD56(bright) NK Cells Is Associated with a CD56(dim)CD16(+) NK Cell-Like Phenotype and Correlates with HIV Viral Load
por: Hong, Henoch S., et al.
Publicado: (2012)

The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56(bright) NK cells
por: Ziegler, Annerose E., et al.
Publicado: (2023)

Single-cell profiling reveals periventricular CD56(bright) NK cell accumulation in multiple sclerosis
por: Rodríguez-Lorenzo, Sabela, et al.
Publicado: (2022)

Regulation of Development of CD56(bright)CD11c(+) NK-like Cells with Helper Function by IL-18
por: Li, Wen, et al.
Publicado: (2013)

PILRα binds an unknown receptor expressed primarily on CD56(bright) and decidual-NK cells and activates NK cell functions
por: Ophir, Yael, et al.
Publicado: (2016)

Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells
por: Tonetti, Cláudia Rodrigues, et al.
Publicado: (2021)

Staphylococcus aureus β-Hemolysin Up-Regulates the Expression of IFN-γ by Human CD56(bright) NK Cells
por: Guan, Zhangchun, et al.
Publicado: (2021)

Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(−) subset
por: Veneziani, Irene, et al.
Publicado: (2022)

Decidual CXCR4(+)CD56(bright)NK cells as a novel NK subset in maternal–foetal immune tolerance to alleviate early pregnancy failure
por: Tao, Yu, et al.
Publicado: (2021)

Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells
por: Schwane, Vera, et al.
Publicado: (2020)

Correction: Toll-like reReceptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(−) subset
Publicado: (2022)

Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype
por: Bhardwaj, Suvercha, et al.
Publicado: (2016)

Evaluation of CD56(dim) and CD56(bright) natural killer cells in peripheral blood of women with IVF failures
por: Mardanian, Farahnaz, et al.
Publicado: (2015)

Human Hepatic CD56(bright) NK Cells Display a Tissue-Resident Transcriptional Profile and Enhanced Ability to Kill Allogenic CD8(+) T Cells
por: Jameson, Gráinne, et al.
Publicado: (2022)

Human Natural Killer Cell Maturation Defect Supports In Vivo CD56(bright) to CD56(dim) Lineage Development
por: Domaica, Carolina Inés, et al.
Publicado: (2012)

CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
por: Reyes, Ryan Michael, et al.
Publicado: (2021)

Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination
por: Peng, Huiyun, et al.
Publicado: (2023)

Increased expression of TIGIT and KLRG1 correlates with impaired CD56(bright) NK cell immunity in HPV16-related cervical intraepithelial neoplasia
por: Nie, You, et al.
Publicado: (2022)

A Subset of PD-1-Expressing CD56(bright) NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer
por: Gascón-Ruiz, Marta, et al.
Publicado: (2023)

CD56(bright) natural killer cells preferentially kill proliferating CD4(+) T cells
por: Lee, Mercede, et al.
Publicado: (2023)

Functional restoration of CD56(bright) NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B
por: Chen, Tao, et al.
Publicado: (2017)

High number of CD56(bright) NK-cells and persistently low CD4(+) T-cells in a hemophiliac HIV/HCV co-infected patient without opportunistic infections
por: Fregni, Giulia, et al.
Publicado: (2013)

CD56(dim)CD16(high) and CD56(bright)CD16(−) cell percentages associated with maximum knee extensor strength and incidence of death in elderly
por: Senpuku, Hidenobu, et al.
Publicado: (2016)

Cytotoxicity of Human Hepatic Intrasinusoidal CD56(bright) Natural Killer Cells against Hepatocellular Carcinoma Cells
por: Hwang, Shin, et al.
Publicado: (2019)

Immune Dysfunctions of CD56(neg) NK Cells Are Associated With HIV-1 Disease Progression
por: Cao, Wen-Jing, et al.
Publicado: (2022)

Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ
por: Jud, Aurelia, et al.
Publicado: (2016)

Human Circulating and Tissue-Resident CD56(bright) Natural Killer Cell Populations
por: Melsen, Janine E., et al.
Publicado: (2016)

The phenotype of CD3–CD56(bright) and CD3–CD56(dim) natural killer cells in systemic lupus erythematosus patients and its relation to disease activity
por: Soelistyoningsih, Dwi, et al.
Publicado: (2022)

Bright’s Disease
por: Clark, Alonzo
Publicado: (1882)

The CXCR3(+)CD56Bright Phenotype Characterizes a Distinct NK Cell Subset with Anti-Fibrotic Potential That Shows Dys-Regulated Activity in Hepatitis C
por: Eisenhardt, Marianne, et al.
Publicado: (2012)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6bst0vqrn1gfl1btplair26cis